排序方式: 共有44条查询结果,搜索用时 15 毫秒
1.
2.
3.
Percutaneous balloon pericardiotomy was reported by Palacious et al in 1991. From 1996-2000, we utilized this procedure as the initial treatment for 17 patients at West Virginia University Hospital in Morgantown with cardiac tamponade who had a high likelihood of recurrence of pericardial effusion. Primary pericardiotomy was successful after the initial procedure in 82% (n = 14) of these patients, so it appears to be an effective non-surgical procedure for patients at high risk for re-accumulation of pericardial effusions. In addition, our comparison at this institution revealed that primary percutaneous pericardial window creation is significantly less costly than pericardiocentesis followed by surgical pericardial window creation. 相似文献
4.
Romesser PB Qureshi MM Shah BA Chatburn LT Jalisi S Devaiah AK Subramaniam RM Truong MT 《Annals of nuclear medicine》2012,26(7):527-534
Objective
To compare the prognostic utility of the 2-[18F] fluoro-2-deoxy-d-glucose (FDG) maximum standardized uptake value (SUVmax), primary gross tumor volume (GTV), and FDG metabolic tumor volume (MTV) for disease control and survival in patients with head and neck squamous cell carcinoma (HNSCC) undergoing intensity-modulated radiotherapy (IMRT).Methods
Between 2007 and 2011, 41 HNSCC patients who underwent a staging positron emission tomography with computed tomography and definitive IMRT were identified. Local (LC), nodal (NC), distant (DC), and overall (OC) control, overall survival (OS), and disease-free survival (DFS) were assessed using the Kaplan?CMeier product-limit method.Results
With a median follow-up of 24.2?months (range 2.7?C56.3?months) local, nodal, and distant recurrences were recorded in 10, 5, and 7 patients, respectively. The median SUVmax, GTV, and MTV were 15.8, 22.2?cc, and 7.2?cc, respectively. SUVmax did not correlate with LC (p?=?0.229) and OS (p?=?0.661) when analyzed by median threshold. Patients with smaller GTVs (<22.2?cc) demonstrated improved 2-year actuarial LC rates of 100 versus 56.4?% (p?=?0.001) and OS rates of 94.4 versus 65.9?% (p?=?0.045). Similarly, a smaller MTV (<7.2?cc) correlated with improved 2-year actuarial LC rates of 100 versus 54.2?% (p?0.001) and OS rates of 94.7 versus 64.2?% (p?=?0.04). Smaller GTV and MTV correlated with improved NC, DC, OC, and DFS, as well.Conclusion
GTV and MTV demonstrate superior prognostic utility as compared to SUVmax, with larger tumor volumes correlating with inferior local control and overall survival in HNSCC patients treated with definitive IMRT. 相似文献5.
6.
Impact of total radiotherapy dose on survival for head and neck Merkel cell carcinoma after resection 下载免费PDF全文
7.
8.
9.
Bhartesh A. Shah Muhammad M. Qureshi Jennifer M. Logue Timothy P. Cooley Ken S. Zaner Scharukh Jalisi Minh Tam Truong 《American journal of otolaryngology》2017,38(4):456-461
Background
To compare cumulative acute toxicity in head and neck cancer patients treated with concurrent chemoradiotherapy alone (CCRT) versus induction chemotherapy (IC) followed by CCRT (I/CCRT).Methods
77 patients underwent definitive CCRT (30 I/CCRT and 47 CCRT). Toxicity was graded using the Common Terminology Criteria for Adverse Events version 4.0. Using the TAME adverse event reporting system, short-term toxicity (T) scores were generated for IC (TIC), CCRT (TCCRT), total treatment duration (TRx), post-treatment period (TPT) and an overall score (Toverall) from treatment start to post treatment period.Results
Acute toxicity other than dysphagia, odynophagia, or dermatitis was reported in 90.0% and 66.0% of I/CCRT and CCRT patients, respectively (P = 0.02). Compared to CCRT group, I/CCRT patients reported greater mean TRx (TRx: 2.11 vs. 2.87, P = 0.01) and Toverall (Toverall: 2.60 vs. 3.70, P = 0.003).Conclusion
I/CCRT patients reported more cumulative acute toxicity during treatment compared to CCRT patients using the TAME reporting system. 相似文献10.
Samuel J. Rubin Diana N. Kirke Waleed H. Ezzat Minh T. Truong Andrew R. Salama Scharukh Jalisi 《American journal of otolaryngology》2017,38(6):654-659